Published on NAVADHI Market Research (https://www.navadhi.com)

Home > India Pharmaceuticals Industry Strategic Research Report 2026-2031

India Pharmaceuticals Industry Strategic Research Report 2026-2031

India Pharmaceuticals Industry Strategic Research Report 2026-2031
Publication ID: 
NAV0826020
Publication Date: 
August 26, 2026
Pages: 
264
Countries: 
India [1]
Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

The India Pharmaceuticals Market (IPM) is estimated at USD 27.8 billion in 2025 (base year), forecast to reach USD 50.0 billion by 2031, at a CAGR of approximately 8.4% across the 2025–2031 forecast period. Real historical data spans 2022–2024 (USD 20.8 billion in 2022), anchored to IQVIA India MIDAS and AIOCD-AWACS retail audit data, not estimated backward from a single base year.

This report independently verifies all 17 profiled companies' financial figures directly against their own official investor relations disclosures and annual reports, following a rigorous data refresh completed in August 2026 that identified and corrected several real discrepancies between commonly-cited estimates and companies' actual reported results.

The GLP-1 sub-segment within Anti-Diabetic therapy is the fastest-growing category in the entire IPM, and this report provides full reconciliation between India-specific IPM-tracked GLP-1 revenue and the broader Global GLP-1 Drug Market report's India country-line figures, since the two measure different channel scopes.

Scope of India Pharmaceuticals Industry Strategic Research Report

  • This report provides forecast data by value (USD Billion) for the India Pharmaceuticals Market (IPM), with 2025 as the base year, real historical data from 2022, and forecasting to 2031.
  • This report provides segment by type (Cardiovascular & Antihypertensive, Anti-Diabetic, Anti-infectives, Gastrointestinal, Vitamins, Minerals & Supplements, Respiratory, CNS / Neurology, Oncology (Prescription), Dermatology, Gynaecology, Other Therapeutic Areas) forecast data by value.
  • This report provides application/channel segments (Retail Pharmacy (Trade generics + Branded), Hospital / Institutional, Jan Aushadhi (Generic public stores), E-Pharmacy (1mg, Apollo, PharmEasy), Diagnostics-linked dispensing, Veterinary (pharma segment)) forecast data by value.
  • This report provides region-wise (West India, North India, South India, East India, Central India) forecast data by value.
  • This report also provides full state-wise forecast data across all five regions.
  • This report identifies key growth drivers and inhibitors affecting the India Pharmaceuticals Market.
  • This report provides company profiles including Company Overview, Key Products & Segments, Financial Performance, Business Strategy, and SWOT Analysis for 264-page-detailed, officially-verified companies.
  • This report provides Porter's Five Forces, PESTLE, and SWOT analysis for the India Pharmaceuticals Market.
  • This report identifies key future trends in the India Pharmaceuticals Market, including the GLP-1 biosimilar revolution and Ayushman Bharat-driven demand expansion.

Segment by Type in India Pharmaceuticals Industry Strategic Research Report

  • Cardiovascular & Antihypertensive
  • Anti-Diabetic
  • Anti-infectives
  • Gastrointestinal
  • Vitamins, Minerals & Supplements
  • Respiratory
  • CNS / Neurology
  • Oncology (Prescription)
  • Dermatology
  • Gynaecology
  • Other Therapeutic Areas

Segment by Application in India Pharmaceuticals Industry Strategic Research Report

  • Retail Pharmacy (Trade generics + Branded)
  • Hospital / Institutional
  • Jan Aushadhi (Generic public stores)
  • E-Pharmacy (1mg, Apollo, PharmEasy)
  • Diagnostics-linked dispensing
  • Veterinary (pharma segment)

Segment by Region in India Pharmaceuticals Industry Strategic Research Report

  • West India
    • Maharashtra
    • Gujarat
    • Goa
  • North India
    • Delhi NCR
    • Uttar Pradesh
    • Punjab
    • Haryana
    • Rajasthan
  • South India
    • Tamil Nadu
    • Karnataka
    • Telangana
    • Andhra Pradesh
    • Kerala
  • East India
    • West Bengal
    • Odisha
    • Bihar
    • Jharkhand
    • North-East India
  • Central India
    • Madhya Pradesh
    • Chhattisgarh

Who can use the India Pharmaceuticals Industry Strategic Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the India Pharmaceuticals Market. Some of the intended users for this report are:

  • C-level executives and Company Directors in pharmaceutical and healthcare companies
  • Industry consultants and Management consultants
  • Marketing professionals and Business development professionals
  • Investment managers, Financial professionals, and Venture Capitalists
  • Bank Managers, M&A Managers, and Auditors
  • Payers, Healthcare Policy Analysts, and Market Access professionals
  • Portfolio Managers and Equity Research Analysts covering Indian pharmaceuticals
  • Anyone operating in the India pharmaceutical value chain, from R&D through retail distribution
  1. Executive Summary
    1. 1.1 India Pharmaceuticals Market (IPM) — Strategic Research Report 2026–2031
    2. 1.2 Preamble and Market Definition
    3. 1.3 Market Sizing and Growth Trajectory
    4. 1.4 Key Structural Demand Drivers
    5. 1.5 Therapy Area Performance: Differentiated Growth Across Categories
    6. 1.6 GLP-1 Drug Market: India's Highest-Growth Emerging Segment
    7. 1.7 Channel Transformation: E-Pharmacy and Institutional Disruption
    8. 1.8 Competitive Landscape: Fragmented Market with Entrenched Leaders
    9. 1.9 Branded Generic Market Structure: Evolution Without Disruption
    10. 1.10 Key Findings Summary
    11. 1.11 Report Scope and Data Integrity
  2. Industry Overview & Forecast
    1. 2.1 The India Pharmaceuticals Market: Structural Growth at Scale
    2. 2.2 Market Size Trajectory and Annual Growth Dynamics
    3. 2.3 Therapy Area Composition and Growth Differentials
    4. 2.3.1 Cardiovascular and Antihypertensive: The Anchor Segment
    5. 2.3.2 Anti-Diabetic: India's Fastest Major Therapy Category
    6. 2.3.3 Anti-Infectives: The Maturing Pillar
    7. 2.3.4 Oncology: The Premium Growth Driver
    8. 2.3.5 Other Significant Therapy Areas
    9. 2.4 Distribution Channel Evolution
    10. 2.4.1 Retail Pharmacy: The Dominant but Slowly Declining Pillar
    11. 2.4.2 Hospital and Institutional: Government Demand Pull Accelerating
    12. 2.4.3 Jan Aushadhi: The Generic Access Wildcard
    13. 2.4.4 E-Pharmacy: The Digital Disruption Channel
    14. 2.5 Regional Demand Architecture
    15. 2.6 Market Concentration and Competitive Structure
    16. 2.7 Structural Inhibitors and Risk Factors
    17. 2.8 Forecast Summary and Strategic Implications
  3. Market Segmentation by Type
    1. 3.1 Overview
    2. 3.2 Cardiovascular and Antihypertensive
    3. 3.3 Anti-Diabetic
    4. 3.4 Anti-Infectives
    5. 3.5 Gastrointestinal
    6. 3.6 Vitamins, Minerals, and Supplements
    7. 3.7 Respiratory
    8. 3.8 CNS and Neurology
    9. 3.9 Oncology: The Premium Growth Engine of the IPM
    10. 3.10 Dermatology and Gynaecology
    11. 3.11 Other Therapeutic Areas
    12. 3.12 Segment Size Hierarchy and Growth Rate Ranking
  4. Market Segmentation by Application
    1. 4.1 Overview and Segmentation Framework
    2. 4.2 Retail Pharmacy
    3. 4.2.1 Scale, Structure, and Historical Trajectory
    4. 4.2.2 Sub-channel Decomposition
    5. 4.2.3 Competitive Dynamics in Retail Pharmacy
    6. India Pharmaceuticals Industry Strategic Research Report 2026-2031
    7. 4.3 Hospital and Institutional Channel
    8. 4.3.1 Market Size and Structural Composition
    9. 4.3.2 Private Hospital Sub-channel
    10. 4.3.3 Government Institutional Sub-channel (Ayushman Bharat / PMJAY)
    11. 4.3.4 ESI/CGHS Sub-channel
    12. 4.4 Jan Aushadhi — Generic Public Stores
    13. 4.4.1 Market Trajectory and Policy Momentum
    14. 4.4.2 Competitive Implications for Branded Generics
    15. 4.5 E-Pharmacy
    16. 4.5.1 Rapid Formalisation of a High-Growth Channel
    17. 4.5.2 Structural Drivers of E-Pharmacy Adoption
    18. 4.5.3 Regulatory Environment for E-Pharmacy
    19. 4.5.4 Competitive Landscape in E-Pharmacy
    20. 4.6 Diagnostics-Linked Dispensing
    21. 4.6.1 An Emerging Adjacency
    22. 4.7 Veterinary Pharmaceuticals
    23. 4.7.1 A Modest but Stable Segment
    24. 4.8 Cross-Channel Analysis and Strategic Implications
    25. 4.8.1 Channel Mix Evolution
    26. 4.8.2 Implications for Manufacturer Strategy
    27. 4.8.3 Policy Risk Concentration
    28. 4.9 Summary Outlook by Application Segment
  5. Regional Market Forecast
    1. 5.1 West India
    2. 5.2 North India
    3. 5.3 South India
    4. 5.4 East India
    5. 5.5 Central India
  6. Country-Level Market Forecast
    1. 6.1 West India
    2. 6.1.1 Maharashtra
    3. 6.1.2 Gujarat
    4. 6.1.3 Goa
    5. 6.2 North India
    6. 6.2.1 Delhi NCR
    7. 6.2.2 Uttar Pradesh
    8. 6.2.3 Punjab
    9. 6.2.4 Haryana
    10. 6.2.5 Rajasthan
    11. 6.3 South India
    12. 6.3.1 Tamil Nadu
    13. 6.3.2 Karnataka
    14. 6.3.3 Telangana
    15. 6.3.4 Andhra Pradesh
    16. 6.3.5 Kerala
    17. 6.4 East India
    18. 6.4.1 West Bengal
    19. 6.4.2 Odisha
    20. 6.4.3 Bihar
    21. 6.4.4 Jharkhand
    22. 6.5 Central India
    23. 6.5.1 Madhya Pradesh
    24. 6.5.2 Chhattisgarh
  7. Growth Drivers & Inhibitors
    1. 7.1 Overview
    2. 7.2 Growth Drivers
    3. 7.2.1 The Non-Communicable Disease Epidemic — Structural Demand Engine
    4. 7.2.2 GLP-1 Receptor Agonist Market — High-Velocity Emerging Segment
    5. 7.2.3 Ayushman Bharat & Government Health Coverage Expansion
    6. 7.2.4 E-Pharmacy Channel Transformation
    7. 7.2.5 Oncology Premiumisation & Specialty Drug Growth
    8. 7.2.6 Production Linked Incentive (PLI) Scheme — Supply-Side Capacity Catalyst
    9. 7.3 Growth Inhibitors
    10. 7.3.1 NPPA Drug Price Control & NLEM Inclusion Risk
    11. 7.3.2 Jan Aushadhi & Trade Generic Penetration
    12. 7.3.3 Fragmented Market Structure & Pricing Competition
    13. 7.3.4 Regulatory & Compliance Complexity — US FDA Warning Letters Affecting R&D Allocation
    14. 7.3.5 INR/USD Depreciation — Revenue Translation & API Import Cost Pressure
    15. 7.3.6 Post-COVID Anti-Infective Volume Normalisation
    16. 7.4 Driver-Inhibitor Balance Assessment
  8. Key Company Profiles
    1. 8.1 Sun Pharmaceutical
    2. 8.1.1 Company Overview
    3. 8.1.2 Key Products & Segments
    4. 8.1.3 Financial Performance (2023–2025)
    5. 8.1.4 Business Strategy
    6. 8.1.5 SWOT Analysis
    7. 8.1.6 Strategic Implications (2025–2031)
    8. 8.2 Cipla
    9. 8.2.1 Company Overview
    10. 8.2.2 Key Products & Segments
    11. 8.2.3 Financial Performance (2023–2025)
    12. 8.2.4 Business Strategy
    13. 8.2.5 SWOT Analysis
    14. India Pharmaceuticals Industry Strategic Research Report 2026-2031
    15. 8.2.6 Strategic Implications (2025–2031)
    16. 8.3 Alkem Laboratories
    17. 8.3.1 Company Overview
    18. 8.3.2 Key Products & Segments
    19. 8.3.3 Financial Performance (2023–2025)
    20. 8.3.4 Business Strategy
    21. 8.3.5 SWOT Analysis
    22. 8.3.6 Strategic Implications (2025–2031)
    23. 8.4 Mankind Pharma
    24. 8.4.1 Company Overview
    25. 8.4.2 Key Products & Segments
    26. 8.4.3 Financial Performance (2023–2025)
    27. 8.4.4 Business Strategy
    28. 8.4.5 SWOT Analysis
    29. 8.4.6 Strategic Implications (2025–2031)
    30. 8.5 Lupin
    31. 8.5.1 Company Overview
    32. 8.5.2 Key Products & Segments
    33. 8.5.3 Financial Performance (2023–2025)
    34. 8.5.4 Business Strategy
    35. 8.5.5 SWOT Analysis
    36. 8.5.6 Strategic Implications (2025–2031)
    37. 8.6 Torrent Pharma
    38. 8.6.1 Company Overview
    39. 8.6.2 Key Products & Segments
    40. 8.6.3 Financial Performance (2023–2025)
    41. 8.6.4 Business Strategy
    42. 8.6.5 SWOT Analysis
    43. 8.6.6 Strategic Implications (2025–2031)
    44. 8.7 Zydus Lifesciences
    45. 8.7.1 Company Overview
    46. 8.7.2 Key Products & Segments
    47. 8.7.3 Financial Performance (2023–2025)
    48. 8.7.4 Business Strategy
    49. 8.7.5 SWOT Analysis
    50. 8.7.6 Strategic Implications (2025–2031)
    51. 8.8 Dr. Reddy's Labs
    52. 8.8.1 Company Overview
    53. 8.8.2 Key Products & Segments
    54. 8.8.3 Financial Performance (2023–2025)
    55. 8.8.4 Business Strategy
    56. 8.8.5 SWOT Analysis
    57. 8.8.6 Strategic Implications (2025–2031)
    58. 8.9 Ipca Laboratories
    59. 8.9.1 Company Overview
    60. 8.9.2 Key Products & Segments
    61. 8.9.3 Financial Performance (2023–2025)
    62. 8.9.4 Business Strategy
    63. 8.9.5 SWOT Analysis
    64. 8.9.6 Strategic Implications (2025–2031)
    65. 8.10 Abbott India
    66. 8.10.1 Company Overview
    67. 8.10.2 Key Products & Segments
    68. 8.10.3 Financial Performance (2023–2025)
    69. 8.10.4 Business Strategy
    70. 8.10.5 SWOT Analysis
    71. India Pharmaceuticals Industry Strategic Research Report 2026-2031
    72. 8.10.6 Strategic Implications (2025–2031)
    73. 8.11 Pfizer India
    74. 8.11.1 Company Overview
    75. 8.11.2 Key Products & Segments
    76. 8.11.3 Financial Performance (2023–2025)
    77. 8.11.4 Business Strategy
    78. 8.11.5 SWOT Analysis
    79. 8.11.6 Strategic Implications (2025–2031)
    80. 8.12 Ajanta Pharma
    81. 8.12.1 Company Overview
    82. 8.12.2 Key Products & Segments
    83. 8.12.3 Financial Performance (2023–2025)
    84. 8.12.4 Business Strategy
    85. 8.12.5 SWOT Analysis
    86. 8.12.6 Strategic Implications (2025–2031)
    87. 8.13 Aurobindo (India formulations)
    88. 8.13.1 Company Overview
    89. 8.13.2 Key Products & Segments
    90. 8.13.3 Financial Performance (2023–2025)
    91. 8.13.4 Business Strategy
    92. 8.13.5 SWOT Analysis
    93. 8.13.6 Strategic Implications (2025–2031)
    94. 8.14 Natco Pharma
    95. 8.14.1 Company Overview
    96. 8.14.2 Key Products & Segments
    97. 8.14.3 Financial Performance (2023–2025)
    98. 8.14.4 Business Strategy
    99. 8.14.5 SWOT Analysis
    100. 8.14.6 Strategic Implications (2025–2031)
    101. 8.15 Biocon (Branded formulations)
    102. 8.15.1 Company Overview
    103. 8.15.2 Key Products & Segments
    104. 8.15.3 Financial Performance (2023–2025)
    105. 8.15.4 Business Strategy
    106. 8.15.5 SWOT Analysis
    107. 8.15.6 Strategic Implications (2025–2031)
    108. 8.16 IOLAB / Piramal (Consumer health)
    109. 8.16.1 Company Overview
    110. 8.16.2 Key Products & Segments
    111. 8.16.3 Financial Performance (2023–2025)
    112. 8.16.4 Business Strategy
    113. 8.16.5 SWOT Analysis
    114. 8.16.6 Strategic Implications (2025–2031)
    115. 8.17 Sanofi India
    116. 8.17.1 Company Overview
    117. 8.17.2 Key Products & Segments
    118. 8.17.3 Financial Performance (2023–2025)
    119. 8.17.4 Business Strategy
    120. 8.17.5 SWOT Analysis
    121. 8.17.6 Strategic Implications (2025–2031)
  9. Competitive Landscape
    1. 9.1 Competitive Landscape Overview
    2. 9.2 Competitive Intensity Assessment
    3. 9.2.1 Player Tier Structure and Revenue Ranges
    4. 9.2.2 Capacity vs. Demand Dynamics
    5. India Pharmaceuticals Industry Strategic Research Report 2026-2031
    6. 9.2.3 Pricing Environment
    7. 9.2.4 Barriers to Entry and Exit
    8. 9.3 Key Player Strategies & Positioning
    9. 9.3.1 Strategic Group Mapping
    10. 9.3.2 Differentiation Strategies by Major Player
    11. 9.3.3 Geographic Strongholds
    12. 9.3.4 M&A and Partnership Activity (2022–Present)
    13. 9.3.5 R&D and Technology Investment Trends
    14. 9.4 Competitive Dynamics & Strategic Outlook
    15. 9.4.1 Emerging Competitive Threats
    16. 9.4.2 Consolidation vs. Fragmentation Outlook
    17. 9.4.3 Competitive Response Matrix
    18. 9.4.4 Strategic Recommendations for 2025–2031
  10. Porter's Five Forces Analysis
    1. 10.1 Threat of New Entrants
    2. 10.2 Bargaining Power of Buyers
    3. 10.3 Bargaining Power of Suppliers
    4. 10.4 Threat of Substitutes
    5. 10.5 Competitive Rivalry
  11. PESTLE Analysis
    1. 11.1 Political
    2. 11.1.1 Government Healthcare Ambition as a Structural Demand Driver
    3. 11.1.2 Production-Linked Incentive (PLI) Scheme — Industrial Policy Backbone
    4. 11.1.3 Drug Price Control and NPPA Regulation
    5. 11.1.4 Geopolitical Positioning — India as Global Pharma Supplier
    6. 11.2 Economic
    7. 11.2.1 Macro Growth and Pharmaceutical Spending Correlation
    8. 11.2.2 Currency Dynamics and USD Revenue Translation Risk
    9. 11.2.3 Out-of-Pocket Healthcare Expenditure — Market Structure Determinant
    10. 11.2.4 Fragmented Market Structure and Consolidation Economics
    11. 11.3 Social
    12. 11.3.1 The NCD Epidemic — Structural Demand Architecture
    13. 11.3.2 Demographic Dividend and Urban Migration
    14. 11.3.3 Healthcare Awareness and Therapy Compliance Evolution
    15. 11.3.4 Cultural Dynamics — The Branded Generic Prescription Culture
    16. 11.4 Technological
    17. 11.4.1 Biosimilar Innovation — Market Transformation at Scale
    18. 11.4.2 E-Pharmacy and Digital Distribution Transformation
    19. 11.4.3 Manufacturing Technology — Quality Assurance and Regulatory Compliance
    20. 11.4.4 Digital Health Integration — AI and Diagnostics
    21. 11.5 Legal
    22. 11.5.1 Drug Price Control — NLEM and Beyond
    23. 11.5.2 Intellectual Property — The Patent Cliff and Compulsory Licensing
    24. 11.5.3 Regulatory Framework — CDSCO and Drug Approval Pathways
    25. 11.6 Environmental
    26. 11.6.1 Climate Risk and Agricultural API Feedstocks
    27. 11.6.2 Environmental Compliance — Manufacturing Discharge and Sustainability
    28. 11.6.3 ESG as a Competitive Differentiator
    29. 11.6.4 Sustainability in Packaging and Logistics
    30. 11.7 PESTLE Summary Assessment
  12. SWOT Analysis
    1. 12.1 Overview and Analytical Framework
    2. 12.2 Strengths
    3. 12.2.1 Structural Demand Engine: World's Largest NCD Epidemic
    4. 12.2.2 Branded Generic Model Creates Durable Competitive Moats
    5. 12.2.3 Deep Manufacturing Capability and API Self-Sufficiency Trajectory
    6. 12.2.4 Biosimilar Leadership Unlocking New Market
    7. 12.3 Weaknesses
    8. 12.3.1 Pricing Controls and DPCO Compression on Branded Margins
    9. 12.3.2 Intense Market Fragmentation Limiting Competitive Rationalization
    10. 12.3.3 Skewed Urban-Rural Distribution Infrastructure
    11. 12.3.4 Dependence on API Imports — Residual China Risk
    12. 12.4 Opportunities
    13. 12.4.1 GLP-1 Biosimilar Market — The Fastest-Growing IPM Sub-Segment
    14. 12.4.2 Ayushman Bharat and Health Insurance Penetration Expanding the Addressable Market
    15. 12.4.3 Oncology Premium Growth — Specialty Drug Premiumisation
    16. 12.4.4 E-Pharmacy Channel Transformation — New Distribution Economics
    17. 12.5 Threats
    18. 12.5.1 Escalating Generic Substitution — Jan Aushadhi and Trade Generic Pressure
    19. 12.5.2 Regulatory Price Intervention Risk — NPPA and DPCO Expansion
    20. 12.5.3 Multinational Competition in High-Value Therapeutic Categories
    21. 12.5.4 Geopolitical and Supply Chain Disruption Risk
    22. 12.6 SWOT Summary Matrix
  13. Future Trends & Outlook
    1. 13.1 Overview
    2. 13.2 Trend One: The GLP-1 Biosimilar Revolution and the Obesity-Diabetes Nexus
    3. 13.3 Trend Two: NCD Epidemic Acceleration Driving Chronic Therapy Growth
    4. 13.4 Trend Three: Ayushman Bharat and Government-Led Demand Expansion
    5. 13.5 Trend Four: E-Pharmacy Channel Disruption and Digital Distribution Transformation
    6. 13.6 Trend Five: Biosimilar Premiumisation and the Specialty Biologics Market
    7. 13.7 Trend Six: Competitive Consolidation and M&A-Driven Market Structure Evolution
    8. 13.8 Outlook Summary: 2026–2031 Key Projections

List of Exhibits

  1. Exhibit 1: 3.1: Forecast of Cardiovascular & Antihypertensive (in USD Bn)
  2. Exhibit 2: 3.2: Forecast of Antihypertensive (in USD Bn)
  3. Exhibit 3: 3.3: Forecast of Cardiac (Statins, Anti-anginal) (in USD Bn)
  4. Exhibit 4: 3.4: Forecast of Anticoagulants & Others (in USD Bn)
  5. Exhibit 5: 3.5: Forecast of Anti-Diabetic (in USD Bn)
  6. Exhibit 6: 3.6: Forecast of Oral Anti-diabetics (Metformin, DPP4) (in USD Bn)
  7. Exhibit 7: 3.7: Forecast of GLP-1 (Ozempic, Mounjaro, Biosim) [IPM-tracked only] (in USD Bn)
  8. Exhibit 8: 3.8: Forecast of Insulin analogues (in USD Bn)
  9. Exhibit 9: 3.9: Forecast of Anti-infectives (in USD Bn)
  10. Exhibit 10: 3.10: Forecast of Antibiotics (Cephalosporins, etc.) (in USD Bn)
  11. Exhibit 11: 3.11: Forecast of Antifungals & Antivirals (in USD Bn)
  12. Exhibit 12: 3.12: Forecast of Gastrointestinal (in USD Bn)
  13. Exhibit 13: 3.13: Forecast of Vitamins, Minerals & Supplements (in USD Bn)
  14. Exhibit 14: 3.14: Forecast of Respiratory (in USD Bn)
  15. Exhibit 15: 3.15: Forecast of CNS / Neurology (in USD Bn)
  16. Exhibit 16: 3.16: Forecast of Oncology (Prescription) (in USD Bn)
  17. Exhibit 17: 3.17: Forecast of Dermatology (in USD Bn)
  18. Exhibit 18: 3.18: Forecast of Gynaecology (in USD Bn)
  19. Exhibit 19: 3.19: Forecast of Other Therapeutic Areas (in USD Bn)
  20. Exhibit 20: 4.20: Forecast of Retail Pharmacy (Trade generics + Branded) (in USD Bn)
  21. Exhibit 21: 4.21: Forecast of Branded Rx (in USD Bn)
  22. Exhibit 22: 4.22: Forecast of Trade Generics / Unbranded (in USD Bn)
  23. Exhibit 23: 4.23: Forecast of OTC / Self-medication (in USD Bn)
  24. Exhibit 24: 4.24: Forecast of Hospital / Institutional (in USD Bn)
  25. Exhibit 25: 4.25: Forecast of Private Hospital (in USD Bn)
  26. Exhibit 26: 4.26: Forecast of Government (Ayushman Bharat/PMJAY) (in USD Bn)
  27. Exhibit 27: 4.27: Forecast of ESI / CGHS (in USD Bn)
  28. Exhibit 28: 4.28: Forecast of Jan Aushadhi (Generic public stores) (in USD Bn)
  29. Exhibit 29: 4.29: Forecast of E-Pharmacy (1mg, Apollo, PharmEasy) (in USD Bn)
  30. Exhibit 30: 4.30: Forecast of Diagnostics-linked dispensing (in USD Bn)
  31. Exhibit 31: 4.31: Forecast of Veterinary (pharma segment) (in USD Bn)
  32. Exhibit 32: 6.32: Forecast of India (in USD Bn)
  33. Exhibit 33: 6.33: Forecast of West India (in USD Bn)
  34. Exhibit 34: 6.34: Forecast of West India (in USD Bn)
  35. Exhibit 35: 6.35: Forecast of North India (in USD Bn)
  36. Exhibit 36: 6.36: Forecast of North India (in USD Bn)
  37. Exhibit 37: 6.37: Forecast of South India (in USD Bn)
  38. Exhibit 38: 6.38: Forecast of South India (in USD Bn)
  39. Exhibit 39: 6.39: Forecast of East India (in USD Bn)
  40. Exhibit 40: 6.40: Forecast of East India (in USD Bn)
  41. Exhibit 41: 6.41: Forecast of Central India (in USD Bn)
  42. Exhibit 42: 6.42: Forecast of Central India (in USD Bn)
  43. Exhibit 43: 6.43: Forecast of Maharashtra (in USD Bn)
  44. Exhibit 44: 6.44: Forecast of Gujarat (in USD Bn)
  45. Exhibit 45: 6.45: Forecast of Goa (in USD Bn)
  46. Exhibit 46: 6.46: Forecast of Delhi NCR (in USD Bn)
  47. Exhibit 47: 6.47: Forecast of Uttar Pradesh (in USD Bn)
  48. Exhibit 48: 6.48: Forecast of Punjab (in USD Bn)
  49. Exhibit 49: 6.49: Forecast of Haryana (in USD Bn)
  50. Exhibit 50: 6.50: Forecast of Rajasthan (in USD Bn)
  51. Exhibit 51: 6.51: Forecast of Tamil Nadu (in USD Bn)
  52. Exhibit 52: 6.52: Forecast of Karnataka (in USD Bn)
  53. Exhibit 53: 6.53: Forecast of Telangana (in USD Bn)
  54. Exhibit 54: 6.54: Forecast of Andhra Pradesh (in USD Bn)
  55. Exhibit 55: 6.55: Forecast of Kerala (in USD Bn)
  56. Exhibit 56: 6.56: Forecast of West Bengal (in USD Bn)
  57. Exhibit 57: 6.57: Forecast of Odisha (in USD Bn)
  58. Exhibit 58: 6.58: Forecast of Bihar (in USD Bn)
  59. Exhibit 59: 6.59: Forecast of Jharkhand (in USD Bn)
  60. Exhibit 60: 6.60: Forecast of Madhya Pradesh (in USD Bn)
  61. Exhibit 61: 6.61: Forecast of Chhattisgarh (in USD Bn)
  62. Exhibit 62: 6.62: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)

Sun Pharmaceutical, Cipla, Alkem Laboratories, Mankind Pharma, Lupin, Torrent Pharma, Zydus Lifesciences, Dr. Reddy's Labs, Ipca Laboratories, Abbott India, Pfizer India, Ajanta Pharma, Aurobindo Pharma, Natco Pharma, Biocon, Piramal Pharma, Sanofi India

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Enterprise license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Enterprise license fee.

 

Enterprise License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

About Us

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Source URL:https://www.navadhi.com/publications/india-pharmaceuticals-industry-strategic-research-report-2026-2031

Links
[1] https://www.navadhi.com/countries/india